Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Impaired class II transactivator expression in mice lacking interferon regulatory factor-2

Abstract

Class II transactivator (CIITA) is required for both constitutive and inducible expression of MHC class II genes. IFN-γ induced expression of CIITA in various cell types is directed by CIITA type IV promoter. The two transactivators, STAT1 and IRF-1, mediate the IFN-γ activation of the type IV promoter by binding to the GAS and IRF-E of the promoter, respectively. In addition to IRF-1, IRF-2, another member of the IRF family, also activates the human CIITA type IV promoter, and IRF-2 cooperates with IRF-1 to activate the promoter in transient transfection assays. IRF-1 and IRF-2 can co-occupy the IRF-E of the human CIITA type IV promoter. To understand the effect of loss of IRF-2 on the endogenous CIITA expression, we assayed for CIITA expression in IRF-2 knock-out mice. Both basal and IFN-γ induced CIITA expression were reduced in IRF-2 knock-out mice. At least half of the amount of inducible CIITA mRNA depends on IRF-2. The reduction of IFN-γ induced CIITA mRNA in IRF-2 knock-out mice was due to the reduction of the type IV CIITA mRNA induction. The reduction of basal CIITA mRNA was apparently due to the reduction of CIITA mRNA originating from other promoters. These data indicate that IRF-2, like IRF-1, plays a critical role in the regulation of the endogenous CIITA gene. The implications in understanding the previously described phenotypes of IRF-2 defective mice are discussed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Basta PV, Sherman PA, Ting JPY . 1987 J. Immunol. 138: 1275–1280

  • Blanck G, Lok M, Kok K, Downie E, Korn JH, Strominger JL . 1990 Hum. Immunol. 29: 150–156

  • Bradley MB, Fernandez JM, Ungers G, Diaz-Berrientos T, Steimle V, Mach B, O'Reilly R, Lee JS . 1997 J. Immunol. 159: 1086–1095

  • Briken V, Ruffner H, Schultz U, Schwarz A, Reis LFL, Strehlow I, Decker T, Staeheli P . 1995 Mol. Cell. Biol. 15: 975–982

  • Chang CH, Fontes JD, Peterlin BM, Flavell RA . 1994 J. Exp. Med. 180: 1367–1374

  • Chang CH, Guerder S, Hong SC, van Ewijk W, Flavell RA . 1996 Immunity 4: 167–178

  • Chin KC, Mao C, Skinner C, Riley JL, Wright KL, Moreno CS, Stark GR, Boss JM, Ting JPY . 1994 Immunity 1: 687–697

  • Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W, Ault KA, Gimbrone MA, Strominger JL, Pober JS . 1984 Proc. Natl. Acad. Sci. USA 81: 4917–4921

  • Fontes JD, Jabrane-Ferrat N, Toth CR, Peterlin BM . 1996 J. Exp. Med. 183: 2517–2521

  • Fontes JD, Jiang B, Peterlin BM . 1997 Nucleic Acids Res. 25: 2522–2528

  • Fontes JD, Kanazawa S, Jean D, Peterlin BM . 1999 Mol. Cell Biol. 19: 941–947

  • Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T . 1999 EMBO J. 18: 5028–5041

  • Fujita T, Sakakibara J, Sudo Y, Miyamoto M, Kimura Y, Taniguchi T . 1988 EMBO J. 7: 3397–3400

  • Glimcher LH, Kara CJ . 1992 Annu. Rev. Immunol. 10: 13–49

  • Goes N, Sims T, Urmson J, Vincent D, Ramassar V, Halloran PF . 1995 J. Immunol. 155: 4559–4566

  • Grieder FB, Vogel SN . 1999 Virology 257: 106–118

  • Harada H, Taniguchi T, Tanaka N . 1998 Biochemie 80: 641–650

  • Hobart M, Ramassar V, Goes N, Urmson J, Halloran PF . 1997 J. Immunol. 158: 4260–4269

  • Koenig Merediz SA, Schmidt M, Hoppe GJ, Alfken J, Meraro D, Levi BZ, Neubauer A, Wittig B . 2000 Nucl. Acids. Res. 28: 4219–4224

  • Kretsovali A, Agalioti T, Spilianakis C, Tzortzakaki E, Merika M, Papamatheakis J . 1998 Mol. Cell Biol. 18: 6777–6783

  • Lew DJ, Decker T, Strehlow I, Darnell JE . 1991 Mol. Cell. Biol. 11: 182–191

  • Lu Y, Boss JM, Hu SX, Xu HJ, Blanck G . 1996 J. Immunol. 156: 2495–2502

  • Mach B, Steimle V, Martinez-Soria E, Reith W . 1996 Annu. Rev. Immunol. 14: 301–331

  • Mahanta SK, Scholl T, Yang FC, Strominger JL . 1997 Proc. Natl. Acad. Sci. USA 94: 6324–6329

  • Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kündig TM, Amakawa R, Kishihara K, Wakeham A, Potter J, Furlonger CL, Narendran A, Suzuki H, Ohashi PS, Paige CJ, Taniguchi T, Mak TW . 1993 Cell 75: 83–97

  • Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM . 1999 Immunity 10: 143–151

  • Muhlethaler-Mottet A, Berardino WD, Otten LA, Mach B . 1998 Immunity 8: 157–166

  • Muhlethaler-Mottet O, Otten LA, Steimle V, Mach B . 1997 EMBO J. 16: 2851–2860

  • Nguyen H, Hiscott J, Pitha PM . 1997 Cytokine Growth Factor Rev. 8: 293–312

  • Nikcevich KM, Piskurich JF, Hellendall RP, Wang Y, Ting JPY . 1999 J. Neuroimmunol. 99: 195–204

  • O'Keefe GM, Nguyen VT, Benveniste EN . 1999 Eur. J. Immunol. 29: 1275–1285

  • Otten LA, Steimle V, Bontron S, Mach B . 1998 Eur. J. Immunol. 28: 473–478

  • Piskurich JF, Linhoff MW, Wang Y, Ting JPY . 1999 Mol. Cell. Biol. 19: 431–440

  • Piskurich JF, Wang Y, Linhoff MW, White LC, Ting JPY . 1998 J. Immunol. 160: 233–240

  • Riley JL, Westerheide SD, Price JA, Brown JA, Boss JM . 1995 Immunity 2: 533–543

  • Rohn WM, Lee YJ, Benveniste EN . 1996 Crit. Rev. Immunol. 16: 311–330

  • Scholl T, Mahanta SK, Strominger JL . 1997 Proc. Natl. Acad. Sci. USA 94: 6330–6334

  • Schoneboom BA, Lee JS, Grieder FB . 2000 J. Interferon Cytokine Res. 20: 205–215

  • Steimle V, Otten LA, Zufferey M, Mach B . 1993 Cell 75: 135–146

  • Steimle V, Siegrist C, Mottet A, Lisowska-Grospierre B, Mach B . 1994 Science 265: 106–109

  • Ting JPY, Baldwin AS . 1993 Curr. Opin. Immunol. 5: 8–16

  • Vaughan PS, Aziz F, van Wijnen AJ, Wu S, Harada H, Taniguchi T, Soprano KJ, Stein JL, Stein GS . 1995 Nature 377: 362–365

  • Xi H, Eason DD, Ghosh D, Dovhey S, Wright KL, Blanck G . 1999 Oncogene 18: 5889–5903

  • Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JPY . 2000 Mol. Cell Biol. 20: 6051–6061

Download references

Acknowledgements

We thank Sue Plyte and Tak Mak (Amgen Institute) for providing the IRF-2 KO mice, Sue Corbitt and R Engelman (College of Medicine Animal Facility, University of South Florida) for help with animal care, Marybeth Colter and the H Lee Moffitt Cancer Center Molecular Biology Core Facility for assistance with DNA sequencing. We also thank Donna Eason for helpful discussion and Ping Lai for technical assistance. This work was supported by grants from National Cancer Institute (RO1CA81497-01) and American Cancer Society (RPG-98-184-01-CIM).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to George Blanck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xi, H., Goodwin, B., Shepherd, A. et al. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene 20, 4219–4227 (2001). https://doi.org/10.1038/sj.onc.1204556

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204556

Keywords

This article is cited by

Search

Quick links